Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Tipranavir (Aptivus®) oral solution, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options. Tipranavir (Aptivus®) oral solution is not suitable for shared care within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | tipranavir (Aptivus®) | ||
| Formulation | 100 mg/ml oral solution | ||
| Reference number | 819 | ||
| Indication | Co-administered with low dose ritonavir, for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors in patients with no other therapeutic options |
||
| Company | Boehringer Ingelheim Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2110 | ||
| NMG meeting date | 17/11/2010 | ||
| AWMSG meeting date | 15/12/2010 | ||
| Ratification by Welsh Government | 27/01/2011 | ||
| Date of issue | 03/02/2011 | ||